Abstract: Schrödinger’s physics-based computational platform accelerates the discovery of high-quality novel molecules for drug discovery and materials design. The platform is used by the company’s internal Therapeutics Group as well as by thousands of biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. As an Applications Scientist on the Life Sciences team, I am a member of the software support organization where I interact with our customers in biotechnology and pharmaceutical companies. In this talk, I will first provide a brief overview of Schrödinger and its unique business model. I will then discuss my day-to-day experience as an Applications Scientist at the company.
Bio: Rezvan Shahoei is an Applications Scientist at Schrödinger. Before joining Schrödinger in 2022, she was a postdoctoral researcher in Dr. Yu-ming M. Huang's group at Wayne State University. Her postdoctoral research involved applying molecular dynamics-based enhanced sampling methods to investigate protein-ligand and protein-membrane binding and unbinding processes. She received her Ph.D. in physics in 2020 from the University of Illinois at Urbana-Champaign under the supervision of Dr. Klaus Schulten and Dr. Emad Tajkhorshid. During her Ph.D., she focused on computational modeling and simulation of pentameric ligand-gated ion channels and their interaction with small molecules.
